Fontolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | interferon gamma |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
326859-36-3  |
| ChemSpider | none |
| UNII |
6J92H2439Z  |
| KEGG |
D04242 |
| Chemical and physical data | |
| Molar mass | ca. 150 kg/mol |
| (what is this?) (verify) | |
Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
- ↑ Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B; et al. (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory bowel diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334.
- ↑ Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov
This article is issued from Wikipedia - version of the 9/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.